Last reviewed · How we verify
SSN Montanide ISA-51
At a glance
| Generic name | SSN Montanide ISA-51 |
|---|---|
| Sponsor | Malaria Vaccine and Drug Development Center |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers (PHASE2)
- Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSN Montanide ISA-51 CI brief — competitive landscape report
- SSN Montanide ISA-51 updates RSS · CI watch RSS
- Malaria Vaccine and Drug Development Center portfolio CI